Pancreatic cancer is a disease with high tumour heterogeneity and dismal prognosis. There are few therapeutic options and many promising drugs have failed in patients, which makes better models to predict drug efficacy a key research priority. Now, a new study shows that patient-derived organoids can be used for molecular and therapeutic profiling and might be useful to predict clinical responses.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Seufferlein, T. & Mayerle, J. Pancreatic cancer in 2015: Precision medicine in pancreatic cancer — fact or fiction? Nat. Rev. Gastroenterol. Hepatol. 13, 74–75 (2016).
Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008).
Hohwieler, M. et al. Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling. Gut 66, 473–486 (2017).
Seino, T. et al. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. Cell Stem Cell 22, 454–467.e6 (2018).
Fujii, M. et al. A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. Cell Stem Cell 18, 827–838 (2016).
Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926 (2018).
Huang, L. et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat. Med. 21, 1364–1371 (2015).
Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
Tiriac, H. et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-18-0349 (2018).
Pushalkar, S. et al. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 8, 403–416 (2018).
Acknowledgements
Work in the lab of T.S. is supported by the DFG-GRK 2254.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Seufferlein, T., Kleger, A. Organoidomics — falling star or new galaxy in pancreatic cancer?. Nat Rev Gastroenterol Hepatol 15, 586–587 (2018). https://doi.org/10.1038/s41575-018-0052-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-018-0052-3
